Preliminary analysis of early clinical efficacy and safety of abiraterone treatment for castration-resistant prostate cancer in Shaanxi area

Kai-jie WU,He WANG,Jian-lin YUAN,Yong-yi CHENG,Tie CHONG,Da-lin HE

DOI: https://doi.org/10.3969/j.issn.1009-8291.2017.01.004

2017-01-01

Abstract:Objective To analyze the early efficacy and safety of abiraterone treatment for the patients who were diagnosed as castration resistant prostate cancer (CRPC),and provide initial experience for further treatment.Methods A total of 50 cases of CRPC patients from the Department of Urology in five large hospitals in Xi'an,Shaanxi province from December 2015th to September 2016th were treated with abiraterone plus prednisone and long-term follow-up.During the treatment,PSA,testosterone,bone scanning,pelvic CT or MRI data as well as side effects of drugs were recorded.The clinical data of 30 eligible cases for at least 12 weeks treatment were analyzed.Results According to the PSAWG standard,the PSA response rate of these 30 cases was 76 ％.For the patients with or without docetaxel chemotherapy,the PSA response rate was 67 ％ and 80％,respectively.For the patients aged 60-70,70-80 and more than 80 years old,the PSA response rate was 85％,90％ and 61％,respectively.For the patients with PSA valued 4-10 ng/mL,10-80 ng/mL and more than 80 ng/mL,the PSA response rate was 100 ％,66％ and 75 ％,respectively.In general,abiraterone was tolerant.The diarrhea,edema,hypokalemia and liver function damage were common.Among 30 cases of patients,3 patients had mild edema,3 patients had abnormal liver function,1 patient had rhabdomyolysis and acute renal injury,and all patients recovered after drug treatment.Conclusions The abiraterone treatment for CRPC patients in Shaanxi area showed a good early efficacy and high safety,and should be recommended in clinic.